Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono to Collaborate with Domain Therapeutics, Universite de Montreal in GPCR-Targeted Drug Discovery
April 20, 2022
- Post-Azilva, Takeda Set to Morph into Rare Disease Specialty Pharma in Japan
April 20, 2022
- Enhertu Gets FDA’s Priority Review for 2nd Line Lung Cancer
April 20, 2022
- Novartis Forms Regional Collab in Nagasaki for CV, Respiratory Diseases
April 19, 2022
- Shionogi, NEC Pair Up for Novel Hepatitis B Therapeutic Vaccine Research
April 19, 2022
- Nippon Boehringer Ingelheim Logs 6.7% Sales Rise in 2021
April 19, 2022
- JCR, Teijin Ditch Regenerative Medicine Deal after Japan PI/II Flop
April 19, 2022
- Otsuka Grabs Rights to Osaka University’s New Antitumor Antibody
April 18, 2022
- Mediceo Gets 6-Month Suspension from National Hospital Organization Bids
April 18, 2022
- Female Manager Ratio at Japan Drug Makers Finally Hits 10%, Foreign Peers Near 25%: Jiho Poll
April 15, 2022
- Astellas’ Padcev Receives Bladder Cancer Nod in Europe
April 15, 2022
- Bayer Yakuhin Sees 2021 Sales Skid 0.6% but Still Reach Target, Retains Spot in Top 10
April 15, 2022
- Shionogi Unit, LPIXEL to Study AI-Based Drug Discovery Tech for Infectious Diseases
April 15, 2022
- Takeda’s HAE Med Takhzyro Hits Targets in Global PIII for Pediatric Patients
April 14, 2022
- Teratogenicity Data for COVID Pill Already Submitted to Japan Regulators: Shionogi
April 14, 2022
- Lumakras Nears Japan Market, Amgen Eyes Simultaneous Launch with US for Next 5 Oncology Drugs: EVP
April 14, 2022
- Innovative Brands to Drive Return to Growth at Lilly Japan after 2 Years of Decline: President
April 13, 2022
- Myovant’s Myfembree Label Expansion Plan Stumbles in FDA Review
April 13, 2022
- Opdivo Gets Adjuvant Nod for Urothelial Cancer in Taiwan
April 13, 2022
- Daiichi Sankyo Espha Launches Follow-On AG for Diart
April 13, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…